Document Detail


Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.
MedLine Citation:
PMID:  10815116     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Panic disorder (PD) may be treated with drugs, psychosocial intervention, or both, but the relative and combined efficacies have not been evaluated in an unbiased fashion. OBJECTIVE: To evaluate whether drug and psychosocial therapies for PD are each more effective than placebo, whether one treatment is more effective than the other, and whether combined therapy is more effective than either therapy alone. DESIGN AND SETTING: Randomized, double-blind, placebo-controlled clinical trial conducted in 4 anxiety research clinics from May 1991 to April 1998. PATIENTS: A total of 312 patients with PD were included in the analysis. INTERVENTIONS: Patients were randomly assigned to receive imipramine, up to 300 mg/d, only (n=83); cognitive-behavioral therapy (CBT) only (n=77); placebo only (n=24); CBT plus imipramine (n=65); or CBT plus placebo (n=63). Patients were treated weekly for 3 months (acute phase); responders were then seen monthly for 6 months (maintenance phase) and then followed up for 6 months after treatment discontinuation. MAIN OUTCOME MEASURES: Treatment response based on the Panic Disorder Severity Scale (PDSS) and the Clinical Global Impression Scale (CGI) by treatment group. RESULTS: Both imipramine and CBT were significantly superior to placebo for the acute treatment phase as assessed by the PDSS (response rates for the intent-to-treat [ITT] analysis, 45.8%, 48.7%, and 21.7%; P=.05 and P=.03, respectively), but were not significantly different for the CGI (48. 2%, 53.9%, and 37.5%, respectively). After 6 months of maintenance, imipramine and CBT were significantly more effective than placebo for both the PDSS (response rates, 37.8%, 39.5%, and 13.0%, respectively; P=.02 for both) and the CGI (37.8%, 42.1%, and 13.0%, respectively). Among responders, imipramine produced a response of higher quality. The acute response rate for the combined treatment was 60.3% for the PDSS and 64.1% for the CGI; neither was significantly different from the other groups. The 6-month maintenance response rate for combined therapy was 57.1% for the PDSS (P=.04 vs CBT alone and P=.03 vs imipramine alone) and 56.3% for the CGI (P=.03 vs imipramine alone), but not significantly better than CBT plus placebo in either analysis. Six months after treatment discontinuation, in the ITT analysis CGI response rates were 41.0% for CBT plus placebo, 31.9% for CBT alone, 19.7% for imipramine alone, 13% for placebo, and 26.3% for CBT combined with imipramine. CONCLUSIONS: Combining imipramine and CBT appeared to confer limited advantage acutely but more substantial advantage by the end of maintenance. Each treatment worked well immediately following treatment and during maintenance; CBT appeared durable in follow-up. JAMA. 2000;283:2529-2536
Authors:
D H Barlow; J M Gorman; M K Shear; S W Woods
Related Documents :
1627026 - Cost and quality effects of alternative treatments for persistent gastroesophageal refl...
2568086 - Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulc...
1641586 - Long-term treatment with 300 mg ranitidine once daily after dilatation of peptic oesoph...
8888436 - Efficacy of sf 68 in the treatment of acute diarrhea. a placebo-controlled trial.
24144536 - Percutaneous vertebroplasty combined with zoledronic acid for the treatment of painful ...
20010356 - Outcomes after transanal repair of rectoceles.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  JAMA : the journal of the American Medical Association     Volume:  283     ISSN:  0098-7484     ISO Abbreviation:  JAMA     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-06-01     Completed Date:  2000-06-01     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2529-36     Citation Subset:  AIM; IM    
Affiliation:
Center for Anxiety and Related Disorders, Boston University, 648 Beacon St, Sixth Floor, Boston, MA 02215, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Analysis of Variance
Antidepressive Agents, Tricyclic / therapeutic use*
Cognitive Therapy*
Combined Modality Therapy
Double-Blind Method
Female
Humans
Imipramine / therapeutic use*
Male
Panic Disorder / diagnosis,  drug therapy,  therapy*
Severity of Illness Index
Grant Support
ID/Acronym/Agency:
MH45964/MH/NIMH NIH HHS; MH45965/MH/NIMH NIH HHS; MH45966/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Antidepressive Agents, Tricyclic; 50-49-7/Imipramine
Comments/Corrections
Comment In:
JAMA. 2000 May 17;283(19):2573-4   [PMID:  10815122 ]
Erratum In:
JAMA 2001 Nov 22-29;284(20):2597
JAMA 2000 Nov 15;284(19):2450

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Payment for immunosuppression after organ transplantation. American Society of Transplantation.
Next Document:  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countrie...